Published in Sarcoma on November 10, 2011
Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing. PLoS One (2016) 1.43
The biology of ewing sarcoma. ISRN Oncol (2013) 1.19
Structure-function based molecular relationships in Ewing's sarcoma. Biomed Res Int (2015) 0.75
Origins and Mechanisms of miRNAs and siRNAs. Cell (2009) 20.77
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature (1992) 7.68
Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 7.10
Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev (2007) 6.91
miRNAs in human cancer. J Pathol (2010) 6.02
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene (2008) 4.11
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 3.81
EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol (2004) 3.33
Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell (2006) 3.29
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol (2009) 3.21
Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A (1993) 3.07
The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest (2009) 3.01
Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem (2011) 2.89
Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res (2010) 2.88
The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol (1993) 2.84
MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics (2010) 2.80
EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res (2008) 2.39
The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell (2002) 2.28
Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer (2009) 2.26
A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med (2009) 2.17
Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol (2009) 2.10
MicroRNA expression signature of human sarcomas. Oncogene (2007) 2.05
The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem (1997) 1.98
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res (2010) 1.96
Regulation of Ets function by protein - protein interactions. Oncogene (2000) 1.93
Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med (2007) 1.82
EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev (2010) 1.81
Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol (2004) 1.77
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics (2007) 1.71
A molecular function map of Ewing's sarcoma. PLoS One (2009) 1.69
Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene (2011) 1.67
MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res (2011) 1.66
A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle (2007) 1.66
Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol (2005) 1.66
Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res (1996) 1.65
Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res (1998) 1.64
Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev (2010) 1.61
EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest (1997) 1.61
Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res (2006) 1.57
Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst (2011) 1.55
High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One (2010) 1.54
The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer (2010) 1.53
Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene (2001) 1.53
Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene (1995) 1.51
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS One (2011) 1.48
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res (2011) 1.48
Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest (1990) 1.44
Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene (2006) 1.42
Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene (1998) 1.41
EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS One (2008) 1.41
EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ (1996) 1.40
Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene (1995) 1.40
EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res (2008) 1.38
IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One (2008) 1.38
Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia (2011) 1.37
MicroRNA in Cancer: The Involvement of Aberrant MicroRNA Biogenesis Regulatory Pathways. Genes Cancer (2010) 1.37
Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clin Cancer Res (2010) 1.36
Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene (2001) 1.35
Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res (2001) 1.34
Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem (2003) 1.34
Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer (2010) 1.34
EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J Biol Chem (2000) 1.33
Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br J Cancer (2009) 1.32
Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res (2006) 1.32
S-MED: sarcoma microRNA expression database. Lab Invest (2010) 1.29
Development of microRNA-145 for therapeutic application in breast cancer. J Control Release (2011) 1.28
Prognostic impact of P53 status in Ewing sarcoma. Cancer (2000) 1.27
Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene (1997) 1.26
Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J Orthop Res (2004) 1.25
Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res (2006) 1.25
The structure and biochemical properties of the human spliceosomal protein U1C. J Mol Biol (2004) 1.23
DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. Oncogene (2008) 1.23
Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Future Oncol (2005) 1.22
EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. Oncogene (2005) 1.19
EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res (2008) 1.17
EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Res (2009) 1.17
Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins. Proc Natl Acad Sci U S A (2007) 1.16
EWS/FLI alters 5'-splice site selection. J Biol Chem (2001) 1.15
A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene (2011) 1.13
The splicing factor U1C represses EWS/FLI-mediated transactivation. J Biol Chem (2000) 1.12
Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin Cancer Res (2010) 1.11
GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS One (2009) 1.10
Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol Ther (2003) 1.10
microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res (2009) 1.08
Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res (2004) 1.08
YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS One (2011) 1.07
DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis. J Biol Chem (2001) 1.05
Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer (1999) 1.05
Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Res (2010) 1.05
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer (2005) 1.04
Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth. Clin Cancer Res (2007) 1.04
Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene (2011) 1.03
Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest (2001) 1.02
Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma. Clin Cancer Res (2006) 1.02
Downstream EWS/FLI1 - upstream Ewing's sarcoma. Genome Med (2010) 1.01
Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model. Int J Cancer (2011) 1.01
Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins. Mol Cell Biol (2006) 1.01
Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein. Oncogene (2003) 1.00
EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res (2008) 1.38
EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. Oncogene (2005) 1.19
Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res (2013) 1.11
Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma. Clin Cancer Res (2010) 1.07
Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Res (2010) 1.05
Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein. Oncogene (2003) 1.00
Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells. Blood (2012) 0.99
Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. Cancer Res (2002) 0.96
miRNA, siRNA, piRNA and argonautes: news in small matters. RNA Biol (2010) 0.88
Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs. Epigenetics (2014) 0.86
The first European interdisciplinary ewing sarcoma research summit. Front Oncol (2012) 0.82
An alternative transcript from the death-associated protein kinase 1 locus encoding a small protein selectively mediates membrane blebbing. FEBS J (2008) 0.78